110 related articles for article (PubMed ID: 30952631)
1. Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come.
Furman C; Hao MH; Prajapati S; Reynolds D; Rimkunas V; Zheng GZ; Zhu P; Korpal M
Cancer Res; 2019 Apr; 79(8):1740-1745. PubMed ID: 30952631
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
[TBL] [Abstract][Full Text] [Related]
3. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Nagasawa JY; Douglas KL; Lai AG; Kahraman M; Bonnefous C; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2015 Nov; 25(22):5163-7. PubMed ID: 26463130
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
[TBL] [Abstract][Full Text] [Related]
5. Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Furman C; Puyang X; Zhang Z; Wu ZJ; Banka D; Aithal KB; Albacker LA; Hao MH; Irwin S; Kim A; Montesion M; Moriarty AD; Murugesan K; Nguyen TV; Rimkunas V; Sahmoud T; Wick MJ; Yao S; Zhang X; Zeng H; Vaillancourt FH; Bolduc DM; Larsen N; Zheng GZ; Prajapati S; Zhu P; Korpal M
Mol Cancer Ther; 2022 Jun; 21(6):890-902. PubMed ID: 35642432
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Guan J; Zhou W; Hafner M; Blake RA; Chalouni C; Chen IP; De Bruyn T; Giltnane JM; Hartman SJ; Heidersbach A; Houtman R; Ingalla E; Kategaya L; Kleinheinz T; Li J; Martin SE; Modrusan Z; Nannini M; Oeh J; Ubhayakar S; Wang X; Wertz IE; Young A; Yu M; Sampath D; Hager JH; Friedman LS; Daemen A; Metcalfe C
Cell; 2019 Aug; 178(4):949-963.e18. PubMed ID: 31353221
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer.
Fanning SW; Greene GL
Endocrinology; 2019 Apr; 160(4):759-769. PubMed ID: 30753408
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
9. X-ray crystallography study and optimization of novel benzothiophene analogs as potent selective estrogen receptor covalent antagonists (SERCAs) with improved potency and safety profiles.
Bai C; Lv Y; Xiong S; Wu S; Qi L; Ren S; Zhu M; Dong H; Shen H; Li Z; Zhu Y; Ye H; Hao H; Xiao Y; Xiang H; Luo G
Bioorg Chem; 2023 Dec; 141():106919. PubMed ID: 37871388
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
Scott JS; Bailey A; Buttar D; Carbajo RJ; Curwen J; Davey PRJ; Davies RDM; Degorce SL; Donald C; Gangl E; Greenwood R; Groombridge SD; Johnson T; Lamont S; Lawson M; Lister A; Morrow CJ; Moss TA; Pink JH; Polanski R
J Med Chem; 2019 Feb; 62(3):1593-1608. PubMed ID: 30640465
[TBL] [Abstract][Full Text] [Related]
11. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
12. Evaluating an ER Degrader for Breast Cancer.
Cancer Discov; 2015 Jul; 5(7):OF15. PubMed ID: 25956960
[No Abstract] [Full Text] [Related]
13. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
[TBL] [Abstract][Full Text] [Related]
14. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
Kulkoyluoglu E; Madak-Erdogan Z
Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
16. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
19. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα
Shea MP; O'Leary KA; Fakhraldeen SA; Goffin V; Friedl A; Wisinski KB; Alexander CM; Schuler LA
Cancer Res; 2018 Apr; 78(7):1672-1684. PubMed ID: 29363543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
